Brind.
  1. Major pharmaceutical companies are heavily investing in R&D for multiple myeloma treatments across Europe.

Pfizer, J&J, BMS, Sanofi, and AbbVie are leading innovation in personalized therapies and are key players in the multiple myeloma treatment market.

1 report, 1 independent Updated Aug 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Pfizer, J&J, BMS, Sanofi, and AbbVie are leading innovation in personalized therapies and are key players in the multiple myeloma treatment market.

Who's involved

What this event is mainly about
PfizerJohnson & JohnsonBristol-Myers Squibb

How it developed

Newest first. Tap a step to see who reported it.
  1. Johnson & Johnson joins the USMN initiative.Sub-event
  2. Major pharma companies are driving innovation in myeloma treatment, with J&J developing CAR T-cell therapies.1 source

Keep exploring

Part of

Major pharmaceutical companies are heavily investing in R&D for multiple myeloma treatments across Europe. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireMultiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 | Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth Multiple Myelo